214 related articles for article (PubMed ID: 37427250)
1. Public health impact and return on investment of Belgium's pediatric immunization program.
Carrico J; Mellott CE; Talbird SE; Bento-Abreu A; Merckx B; Vandenhaute J; Benchabane D; Dauby N; Ethgen O; Lepage P; Luyten J; Raes M; Simoens S; Van Ranst M; Eiden A; Nyaku MK; Bencina G
Front Public Health; 2023; 11():1032385. PubMed ID: 37427250
[TBL] [Abstract][Full Text] [Related]
2. Fiscal analysis of the pediatric immunization program in Belgium applying a lifetime government perspective framework.
Kotsopoulos N; Bento-Abreu A; Bencina G; Connolly MP
Expert Rev Pharmacoecon Outcomes Res; 2024 Mar; 24(3):437-445. PubMed ID: 38231471
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and return on investment of the pediatric immunization program in Poland.
Mellott CE; Jaworski R; Carrico J; Talbird SE; Dobrowolska I; Golicki D; Bencina G; Clinkscales M; Karamousouli E; Eiden AL; Sabale U
Expert Rev Vaccines; 2023; 22(1):1114-1125. PubMed ID: 37909887
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of the routine childhood immunization program in the United States, 2009.
Zhou F; Shefer A; Wenger J; Messonnier M; Wang LY; Lopez A; Moore M; Murphy TV; Cortese M; Rodewald L
Pediatrics; 2014 Apr; 133(4):577-85. PubMed ID: 24590750
[TBL] [Abstract][Full Text] [Related]
5. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
[TBL] [Abstract][Full Text] [Related]
6. Value of the Immunization Program for Children in the 2017 US Birth Cohort.
Carrico J; La EM; Talbird SE; Chen YT; Nyaku MK; Carias C; Mellott CE; Marshall GS; Roberts CS
Pediatrics; 2022 Sep; 150(3):. PubMed ID: 35821603
[TBL] [Abstract][Full Text] [Related]
7. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
8. Health and Economic Evaluation of Vaccination Against Pertussis in China: A 40-Year Analysis.
Wu D; Jing R; Zheng H; He K; Li Y; Yu W; Yin Z; Fang H
Value Health; 2023 May; 26(5):666-675. PubMed ID: 36328326
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness and budget impact of universal varicella vaccination in Russia.
Marijam A; Safonova E; Scherbakov M; Shpeer E; Van Oorschot D; Rudakova A; Tatochenko V; Briko N
Hum Vaccin Immunother; 2022 Nov; 18(5):2045152. PubMed ID: 35258445
[TBL] [Abstract][Full Text] [Related]
10. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis.
Zhou F; Bisgard KM; Yusuf HR; Deuson RR; Bath SK; Murphy TV
Pediatrics; 2002 Oct; 110(4):653-61. PubMed ID: 12359777
[TBL] [Abstract][Full Text] [Related]
11. National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.
Hill HA; Elam-Evans LD; Yankey D; Singleton JA; Kolasa M
MMWR Morb Mortal Wkly Rep; 2015 Aug; 64(33):889-96. PubMed ID: 26313470
[TBL] [Abstract][Full Text] [Related]
12. Economic evaluation of use of diphtheria, tetanus, and acellular pertussis vaccine or diphtheria, tetanus, and whole-cell pertussis vaccine in the United States, 1997.
Ekwueme DU; Strebel PM; Hadler SC; Meltzer MI; Allen JW; Livengood JR
Arch Pediatr Adolesc Med; 2000 Aug; 154(8):797-803. PubMed ID: 10922276
[TBL] [Abstract][Full Text] [Related]
13. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile.
Levine OS; Ortiz E; Contreras R; Lagos R; Vial P; Misraji A; Ferreccio C; Espinoza C; Adlerstein L; Herrera P
Am J Epidemiol; 1993 Jun; 137(11):1221-8. PubMed ID: 8322763
[TBL] [Abstract][Full Text] [Related]
14. Non-specific effects of measles, mumps, and rubella (MMR) vaccination in high income setting: population based cohort study in the Netherlands.
Tielemans SMAJ; de Melker HE; Hahné SJM; Boef AGC; van der Klis FRM; Sanders EAM; van der Sande MAB; Knol MJ
BMJ; 2017 Aug; 358():j3862. PubMed ID: 28855159
[No Abstract] [Full Text] [Related]
15. Cost-Minimization and Budget Impact Analysis of a Hexavalent Vaccine (Hexaxim®) in the Colombian Expanded Program on Immunization.
Romero M; Góngora DS; Caicedo ML; Benchabane D; Lopez JG
Value Health Reg Issues; 2021 Dec; 26():150-159. PubMed ID: 34474265
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
17. Impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccination in India.
Clark AD; Griffiths UK; Abbas SS; Rao KD; Privor-Dumm L; Hajjeh R; Johnson H; Sanderson C; Santosham M
J Pediatr; 2013 Jul; 163(1 Suppl):S60-72. PubMed ID: 23773596
[TBL] [Abstract][Full Text] [Related]
18. Cost-minimization analysis of DTaP-IPV-Hib combination vaccine in China: A nationwide cross-sectional study.
Liu B; Cao B; Wang C; Sun T; Miao Y; Zhang S; Zhao T; Cui F
J Med Virol; 2023 Jan; 95(1):e28358. PubMed ID: 36448181
[TBL] [Abstract][Full Text] [Related]
19. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
[TBL] [Abstract][Full Text] [Related]
20. Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran.
Teimouri F; Kebriaeezadeh A; Zahraei SM; Gheiratian M; Nikfar S
Daru; 2017 Jan; 25(1):1. PubMed ID: 28088246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
